Wave Life Sciences Ltd. Q2 FY2026 earnings call

• Core Pipeline Progress (WVE-007 for Obesity): Positive single-dose Phase 1 data showed robust, durable target silencing of up to 88% lasting at least 7.5 months, supporting potential once or twice yearly dosing. A single dose delivered substantial reductions in visceral and subcutaneous fat while preserving muscle mass (a key differentiation from incretin therapies), with a 16.5% improvement in the visceral fat-to-muscle ratio (VMR), a novel composite body composition biomarker. The FDA accepted the Phase 2a trial amendment, and dosing is now underway in patients with BMI 35-50 (with and without diabetes) across two dose levels; additional combination therapy and post-incretin maintenance trials are on track to initiate in 2026. The program has three core development goals: confirm efficacy in obese patients with comorbidities, evaluate combination with incretins for deeper weight loss, and test maintenance therapy to prevent weight regain after incretin cessation, addressing high 1-year GLP-1 discontinuation rates.
• Core Pipeline Progress (WVE-006 for AETD/AATD): RNA editing candidate for homozygous ZZ-AATD, which addresses both lung and liver manifestations of the disease (unlike current approved IV augmentation therapy that only treats lung symptoms). Enrollment and dosing are complete across all three dose cohorts of the ongoing Restoration 2 Phase 2 trial; 600mg monthly cohort data is expected in H2 2026. The FDA granted a requested face-to-face meeting for end of summer 2026 to discuss a potential accelerated approval pathway. WVE-006 delivers only wild-type functional AAT protein without bystander editing, a key safety differentiation from permanent DNA editing approaches.
• Core Pipeline Progress (WVE-008 for PNPLA3 Liver Disease): Second RNA editing candidate for homozygous PNPLA3 I148M liver disease, which affects 9 million people in the US and Europe who face a 9-fold higher risk of liver death. Unlike silencing approaches that eliminate all PNPLA3 protein (leaving residual inflammation/fibrosis and potentially worsening disease), WVE-008 corrects the harmful variant to restore functional wild-type protein. Preclinical data presented at EASL 2026 demonstrated >50% editing of the target transcript (the threshold expected to reduce liver disease risk) and greater reductions in lipid droplet density than siRNA approaches. The program remains on track for a CTA submission in 2026.
• Platform and Early Pipeline: Management continues to advance proprietary oligonucleotide chemistry and bi-functional modality work; an Investor Day in fall 2026 will share new platform advancements. The company is actively exploring partnership opportunities for its DMD candidate N531 (for exon 53 skipping) and HD program ahead of NDA filing, given evolving regulatory and commercial dynamics in the DMD space.
• Financial Position: The company ended Q2 2026 with $490.6 million in cash, which is expected to fund operations into Q3 2028, not including potential future milestone payments from the GSK collaboration.

Wave Life Sciences is a clinical-stage biotech focused on RNA therapeutics, with all revenue generated from its ongoing collaboration agreement with GSK. In Q2 2026, total revenue was $2.3 million, down from $8.7 million in the year-ago quarter. Research and development (R&D) expenses were $51.3 million, an increase from $43.5 million in Q2 2025, driven by higher investment in advancing clinical programs and the RNA editing pipeline. General and administrative (G&A) expenses were $24.8 million, up from $18 million in Q2 2025. Net loss for the quarter was $69.4 million, compared to a net loss of $50.5 million in Q2 2025. As of the end of Q2 2026, the company held $490.6 million in cash, cash equivalents, and marketable securities.

• WVE-007: Additional Phase 1 600mg cohort data will be shared in 2026; the company will provide formal guidance on data release timelines for the Phase 2a trial once enrollment reaches a steady state, though there is potential for readouts as early as 2026. Combination and maintenance trials for WVE-007 remain on track to initiate in 2026.
• WVE-006: 600mg monthly cohort data from the Phase 2 Restoration 2 trial will be shared in H2 2026; the FDA meeting to discuss an accelerated approval pathway is scheduled for end of summer 2026, with an update provided after the company receives written feedback.
• WVE-008: CTA submission for the first-in-human trial remains on track for 2026.
• No changes to prior cash runway guidance: existing cash is expected to fund operations into Q3 2028.
• A fall 2026 Investor Day will be held to present new platform advancements and pipeline updates.

• Clinical development risk: Success in early-phase trials does not guarantee positive results in larger late-phase trials; trial enrollment timelines could shift, potentially delaying data readouts and regulatory milestones.
• Regulatory risk: The FDA may not agree to the proposed accelerated approval pathway for WVE-006, or may require larger, longer-duration trials than currently expected. Regulators may also not accept the novel VMR biomarker or body composition endpoints for WVE-007 approval.
• Competitive risk: Other companies are developing similar approaches for obesity, AATD, and PNPLA3 liver disease, including DNA editing and siRNA therapies, which may reach the market first or have more favorable efficacy/safety profiles.
• Partnership risk: The company may not be able to secure a favorable partnership for N531 (DMD), which would delay or alter plans for NDA filing and commercialization.
• Safety risk: While early data has shown a favorable safety profile, larger trials may identify unexpected adverse events that could halt or slow development.

Q: For WVE-007's Phase 2a trial, is the primary goal to hit the 5% weight loss threshold vs placebo for obesity approval, and how does the company expect to differentiate its combination data from other programs in the space? / A: The Phase 2a is designed to cross the 5% weight loss regulatory threshold for obesity. The company expects its greater potency (3x higher preclinical ED50) and more durable knockdown relative to competitors will translate to better efficacy data. The biggest differentiation is the unique post-incretin maintenance therapy opportunity, which addresses a large unmet need created by high GLP-1 discontinuation rates. The trial also includes assessments for cardiometabolic indications beyond obesity, including liver fat reduction for MASH, HbA1c for type 2 diabetes, and lipid levels.

Q: Will the end-of-summer FDA meeting for WVE-006 be the first feedback on a potential accelerated approval pathway? / A: Yes, this is the first requested meeting with the FDA to discuss an accelerated approval pathway for WVE-006, and the FDA granted a face-to-face discussion rather than a written response. The company will provide a public update after the meeting and after receiving formal written feedback from the agency.

Q: What is the rationale for the 50% editing threshold for WVE-008 in PNPLA3 liver disease? / A: The threshold is directly anchored in human genetics: homozygous carriers of the harmful I148M variant have a 9-fold higher risk of liver death, while heterozygous carriers (who have ~50% functional wild-type protein) have only minimal increased risk, translating to an ~80% reduction in risk when moving from homozygous to heterozygous status. This 50% editing threshold matches the protective genetic state, and higher editing would only improve outcomes. This approach also addresses the risk seen with silencing, which eliminates all PNPLA3 protein and can worsen inflammation and fibrosis.

Q: Why is Wave now pursuing a partnership for its DMD candidate N531 ahead of NDA filing, and will Wave file the NDA without a partner? / A: Wave has consistently planned to seek a partner for N531 since the start of 2026, and discussions are ongoing. The evolving DMD landscape, including the upcoming full approval filing for an existing competing PMO exon 53 therapy, prompted the decision to advance partnering discussions first. Wave will continue to evaluate the regulatory pathway and will make a decision on filing without a partner after assessing the current landscape and partnering progress.

Q: How does Wave rank the cardiometabolic signals it is tracking for WVE-007 in the Phase 2a trial? / A: All endpoints are important, as visceral fat reduction (WVE-007's core mechanism) is linked to all measured cardiometabolic benefits. The company will follow the data to prioritize the indication where WVE-007 is most differentiated, and advance along the fastest possible regulatory pathway. For example, MASH could be an attractive opportunity for accelerated approval if meaningful liver fat reduction signals are observed.